NCT06285357 The Effect of the Association EGCG, Folic Acid and Vitamin B12 in Preventing the Persistence of HPV Infection.
| NCT ID | NCT06285357 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Lo.Li.Pharma s.r.l |
| Condition | HPV Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-02-19 |
| Primary Completion | 2026-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-02-19 with a primary completion date of 2026-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to test the effect of the administration of a dietary supplement consisting of epigallocatechin gallate (EGCG), vitamin B12 and folic acid in the treatment of infections with papilloma virus of the cervix.
Eligibility Criteria
Inclusion Criteria: * HR-HPV DNA test positivity Exclusion Criteria: * No HSIL
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06285357 clinical trial?
This trial is open to female participants only, aged 25 Years or older, up to 65 Years, studying HPV Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06285357 currently recruiting?
Yes, NCT06285357 is actively recruiting participants. Contact the research team at giovanni.grandi@unimore.it for enrollment information.
Where is the NCT06285357 trial being conducted?
This trial is being conducted at Modena, Italy.
Who is sponsoring the NCT06285357 clinical trial?
NCT06285357 is sponsored by Lo.Li.Pharma s.r.l. The trial plans to enroll 100 participants.